Abstract. Serum Bone Gla Protein (BGP) levels were measured by both immunoradiometric assay (IRMA) and radioimmunoassay (RIA) to investigate the effect of intermittent 1,25(OH)2D3 administration to dialysis patients who could not tolerate an increase in an active vitamin D3 dose and/or calcium to control secondary hyperparathyroidism due to hypercalcemia. The administration of active vitamin D3 gradually increased the serum BGP to more than 3 times the original level by the 8th week. At the 12th week after starting the active vitamin D3 therapy, mean BGP was about twice the original level, which was about half the maximum level at the 8th week. The BGP (IRMA)/BGP (RIA) ratio was increased significantly at 4th and 8th weeks compared to the original level. During this period, serum calcium, phosphorous, or intact molecule PTH (I-PTH) levels showed jnsignificant changes, with a slight reduction in the mid molecule PTH (m-PTH) level, and a significant reduction in ALP. Serum BUN and creatinine levels were not changed significantly. These data suggest that BGP was increased through direct stimulation of osteoblasts by the active vitamin D3, and the increase was not due to deterioration of secondary hyperparathyroidism.
RENAL osteodystrophy is one of the major complications in patients under regular hemodialysis. The administration of active vitamin D3, strict control of the serum phosphorous level, and the reduction of aluminum accumulation in the body are known to ameliorate renal osteodystrophy. Patients often have a higher serum calcium level after long-term hemodialysis, so that enough active vitamin D3 and/or calcium cannot be administered to control the progression of secondary hyperparathyroidism.
Active vitamin D3 is known to reduce PTH synthesis [1] , and its secretion [2] . Intermittent treatment with high dose active vitamin D3 reduces the PTH level without causing severe hypercalcemia [3] , and the treatment is widely accepted as "chemical parathyroidectomy", although the treatment does not seem to be effective for patients with severe secondary hyper- 
Discussion
BGP is synthesized in osteoblasts, released into the blood stream, and metabolized by the kidneys [9] . The serum BGP level is one of the markers of osteoblastic function, and correlates with bone turnover [5] . The level is reported to be increased in patients with hyperparathyroidism or renal failure. Serum BGP increases with age, probably due to the increased frequency of fracture by osteoporosis or the increase in bone turnover after menopause [10] , but other groups reported that the level decreased with age in both sexes [11] .
Judging from the high BGP levels in dialysis patients, the sex or age differences would be so small that they can be ignored in the evaluation of bone metabolism in adult dialysis patients.
The intravenous administration of calcitriol to patients with refractory ostitis fibrosa secondary to chronic renal failure is effective in reducing degree of secondary hyperparathyroidism and in ameliorating bone changes [3] . In the previous report, the serum BGP level was increased after long-term 1-alpha(OH)D3 therapy [7] , but shortterm change in BGP was not reported in that paper.
To evaluate bone metabolism sequentially, the measurement of the serum BGP is clinically useful. BGP can be measured easily by RIA. As the serum BGP of dialysis patients measured by RIA consists of at least 4 to 6 different molecules including fragments [7] , the serum BGP level of the intact molecule form may reflect the real bone metabolism in dialysis patients. As commercially available RIAs usually utilize the cross reaction with antibody to cow BGP, the serum level may be inappropriately high, and mislead in the estimation of bone metabolism in dialysis patients, because of a cross reaction with BGP fragments. The monoclonal antibodies utilized for IRMA in the present study were reactive with BGP (34-49) and BGP , and the BGP (IRMA) levels would more precisely show the bone metabolism of these patients. The significant increase in serum BGP due to the treatment proved that osteoblasts of dialysis patients can be stimulated for 8 weeks, followed by a reduction in the stimulation. The increase in BGP with insignificant changes in the PTH level and/or renal function suggests that the increase in bone metabolism was not caused by the deterioration of secondary hyperparathyroidism or renal function. The significant increase in the ratio of BGP (IRMA) to BGP (RIA) suggests that the increase in the BGP level was due to increased formation of intact BGP by osteoblasts, although a reduction in BGP metabolism cannot be ruled out completely.
BGP is a vitamin D dependent protein and active vitamin D3 increased BGP production in an in vitro study [ 12] . Although the serum BGP level correlates with the serum PTH level, evidence that PTH directly stimulates BGP production in vivo is lacking. Firstly, PTH suppresses BGP production in vitro [ 12] [14, 15] and in vivo [ 16] . Amelioration of renal osteodystrophy may be one explanation. During the investigation, mild hypercalcemia occurred. Although hypercalcemia could be controlled easily by temporary reduction of the vitamin D3 dose, the incidence or degree of ectopic calcification might be increased during long term treatment.
Therefore, the clinical value of intermittent treatment of dialysis patients with active vitamin D3, especially long-term treatment, remained to be determined.
